Trial Profile
Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary) ; Doxorubicin
- Indications Early breast cancer
- Focus Adverse reactions
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 30 Jun 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2016 ClinicalTrials.gov record
- 30 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.